Exchange: NASDAQ·Updated 07:53 PM EST
IMTX logo

IMTX Immatics N.V

$6.39
$0.13
(1.99%)
Today
Closed $6.39
$0.12
(1.88%)
After Hours
Reported EarningsNov 10
Mkt Cap$956.17M
Vol586,385.00

About IMTX

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.
25

Bearish Sentiment

How do you feel about IMTX?

buylocellhi
$IMTX under the radar gem, will be over $7 soon, not advice invest in your own risk Discl: long
1
AlertsAndNews
$IMTX IMTX Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting "IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profile IMA402 achieved a cORR of 32%, 12.5 months median DOR and a 1-year OS rate of 91% in advanced melanoma patients with high PRAME expression"
1

Advertisement|Remove ads.